Potent twice-weekly rifapentine-containing regimens in murine tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 174, Issue 1, 2006, Pages 94-101

  Rosenthal, Ian M ^a   Williams, Kathy ^a   Tyagi, Sandeep ^a   Peloquin, Charles A ^a   Vernon, Andrew A ^a   Bishai, William R ^a   Grosset, Jacques H ^a   Nuermberger, Eric L ^a  

^a NONE

Author keywords

Moxifloxacin; Rifampin; Rifapentine; Treatment; Tuberculosis

Indexed keywords

ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BODY WEIGHT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; MAXIMUM ALLOWABLE CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT DURATION; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; ISONIAZID; MICE; MICE, INBRED BALB C; PYRAZINAMIDE; QUINOLINES; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 33745474234     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200602-280OC     Document Type: Article

References (40)

1. British Thoracic Society. A controlled trial of 6-months chemotherapy in pulmonary tuberculosis. Final Report: results during the 36 months and after the end of chemotherapy and beyond. Br J Dis Chest 1984;78:330-336.
2. Frieden T, Sterling T, Munsiff S, Watt C, Dye C. Tuberculosis. Lancet 2003;362:887-899.
3. Nardell E, Rubin E. Once upon a time . . . improved intermittent therapy for tuberculosis-fact or fable? Am J Respir Crit Care Med 2005;172:1361-1362.
4. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
5. World Health Organization. Treatment of tuberculosis: guidelines for national programmes, 3rd ed. Geneva, Switzerland: World Health Organization; 2003. Publication No. WHO/CDS/TB/2003.313.
6. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemoptherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987;136:1339-1342.
7. Chang K, Leung C, Yew W, Ho S, Tam C. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004;170:1124-1130.
8. Li J, Munsiff S, Driver C, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997. Clin Infect Dis 2005;41:83-91.
9. Rosenthal I, Williams K, Tyagi S, Vernon A, Peloquin C, Bishai W, Grosset J, Nuermberger E. Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis. Am J Respir Crit Care Med 2005;172:1457-1462.
10. Heifets L. Microbiological aspects of rifapentine. Drugs Today (Barc) 1999;35:7-15.
11. Anonymous. Rifapentine (Priftin) data on file [package insert]. Kansas City, MO: Hoechst Marion Roussel; 1998.
12. Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet 2002;360:528-534.
13. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999;353:1843-1847.
14. Weiner M, Burman W, Vernon A, Benator D, Peloquin C, Khan A, Weis S, King B, Shah N, Hodge T, and the Tuberculosis Trials Consortium. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003;167:1341-1347.
15. Gordin F. Rifapentine for the treatment of tuberculosis. Am J Respir Crit Care Med 2004;169:1176-1177.
16. Daniel N, Lounis N, Ji B, O'Brien R, Vernon A, Geiter L, Szpytma M, Truffot-Pernot C, Hejblum G, Grosset J. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Am J Respir Crit Care Med 2000;161:1572-1577.
17. Jayaram R, Gaonkar S, Kaur P, Suresh B, Mahesh B, Jayashree R, Nandi V, Bharat S, Shandil R, Kantharaj E, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003;47:2118-2124.
18. Peloquin C. What is the "right" dose of rifampin? Int J Tuberc Lung Dis 2003;7:3-5.
19. Burman W, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40:327-341.
20. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2003;169:421-426.
21. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien R, Vernon A, Chaisson R, Bishai W, Grosset J. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004;170:1131-1134.
22. Ji B, Truffot-Pernot C, Lacroix C, Raviglione M, O'Brien R, Olliaro P, Roscigno G, Grosset J. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993;148:1541-1546.
23. Assandri A, Ratti B, Cristina T. Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit. J Antibiot 1984;37:1066-1075.
24. Adachi Y, Nanno T, Yamashita M, Ueshima S, Yamamoto T. Induction of rat liver bilirubin-conjugating enzymes and glutathione S-transferase by rifampicin. Gastroenterol Jpn 1985;20:104-110.
25. Heifets L, Lindholm-Levy P, Flory M. Bacterial activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis 1990;141:626-630.
26. Bryskier A. Ansamycins. In: Bryskier A, editor. Antimicrobial agents: antibacterials and antifungals, 10th ed. Washington, DC: ASM Press; 2005. pp. 906-924.
27. Bock N, Sterling T, Hamilton C, Pachucki C, Wang Y, Conwell D, Mosher A, Samuels M, Vernon A. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med 2002;165:1526-1530.
28. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983;5:S440-S446.
29. Grosset J, Ji B. Experimental chemotherapy of mycobacterial diseases. In: Gangadharam PRJ, Jenkins PA, editors. Mycobacteria II: chemotherapy. New York: Chapman & Hall; 1998. pp.51-97
30. Keung A, Reith K, Eller M, McKenzie K, Cheng L, Weir S. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I. Int J Tuberc Lung Dis 1999;3:426-436.
31. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978;18:108-127.
32. Acocella G, Pagani V, Marchetti M, Baroni G, Nicolis F. Kinetic studies on rifampicin: serum concentration analysis in subjects treated with different oral doses over a period of two weeks. Chemotherapy 1971;16:356-370.
33. Loos U, Musch E, Jensen J, Mikus G, Schwabe HK, Eichelbaum M. Pharmacokinetics of oral and intraveneous rifampicin during chronic administration. Klin Wochenschr 1985;63:1205-1211.
34. Langdon G, Wilkins JJ, Smith PJ, McIlleron H. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. Int J Tuberc Lung Dis 2004;8:862-867.
35. Verbist L. Rifampicin activity in vitro and in established tuberculosis in mice. Acta Tuberc Pneumol Belg 1969;3-4:397-412.
36. Long M, Snider D, Farer L. US Public Health Service cooperative trial of three rifampin-isoniazid regimens in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979;119:879-894.
37. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J, Ji B. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 1993;37:407-413.
38. Lenearts A, Chase S, Chmielewski A, Cynamon M. Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. Antimicrob Agents Chemother 1999;43:2356-2360.
39. Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992;36:548-551.
40. Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, Lahart C, Weis S, King B, Mangura B, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2005;173:350-356.